The development and characterization of solid dispersion formulations of Azilsartan medoxomil (AZM) is an important approach to enhance the dissolution rate and oral bioavailability of this poorly water-soluble antihypertensive drug. The aim of this research was to develop modified dosage form of poorly water-soluble antihypertensive drug Azilsartan medoxomil, with the goal of improving their solubility and bioavailability. Azilsartan medoxomil with low water solubility, was selected for the study. Various formulations were prepared using method, including solid dispersion. The prepared formulations were characterized using various techniques, including Fourier transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC). The results showed that the modified dosage forms significantly improved the solubility and dissolution of the poorly water-soluble antihypertensive drugs by using solid dispersion. The solid dispersion formulation AZLC2 was found to be the most effective in improving the solubility and dissolution of the drugs. Overall, the study demonstrated the potential of modified dosage forms for improving the bioavailability and efficacy of poorly water-soluble drugs, which could lead to improved therapeutic outcomes for patients with hypertension.